Cataract News and Research RSS Feed - Cataract News and Research

A cataract is a clouding of the lens in the eye that affects vision. Most cataracts are related to aging. Cataracts are very common in older people. By age 80, more than half of all Americans either have a cataract or have had cataract surgery.

A cataract can occur in either or both eyes. It cannot spread from one eye to the other.
FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). [More]
Japanese surgeons first to implant InnFocus MicroShunt

Japanese surgeons first to implant InnFocus MicroShunt

InnFocus, Inc. reported today that the first two surgeries have been conducted in Japan in a clinical investigational study using the InnFocus MicroShunt™ glaucoma drainage implant. [More]
Around 9.6% of women diagnosed with dry eye disease, treated with artificial tear eye drops

Around 9.6% of women diagnosed with dry eye disease, treated with artificial tear eye drops

The symptoms of dry eye disease include the sensation of grit in the eye, frequently accompanied by itching, burning and visual disturbance. The causes are poorly understood. [More]
Bypassing politics, insurers pay for end of life talks

Bypassing politics, insurers pay for end of life talks

These doctor-patient conversations had been labeled "death panels" by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were rejected by outside auditors. [More]
Tiny eye implant enables patients to battle glaucoma

Tiny eye implant enables patients to battle glaucoma

For the 2.2 million Americans battling glaucoma, the main course of action for staving off blindness involves weekly visits to eye specialists who monitor - and control - increasing pressure within the eye. [More]
DNA testing for congenital cataracts can accurately diagnose diseases linked to childhood blindness

DNA testing for congenital cataracts can accurately diagnose diseases linked to childhood blindness

Researchers in the United Kingdom have demonstrated that advanced DNA testing for congenital cataracts can quickly and accurately diagnose a number of rare diseases marked by childhood blindness, according to a study published online today in Ophthalmology, the journal of the American Academy of Ophthalmology. [More]
Omeros reports net loss of $18 million for second quarter 2014

Omeros reports net loss of $18 million for second quarter 2014

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014. [More]
European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema. [More]
Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]
FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]

Researchers create high-precision software for better detection of eye sensitivity

Researchers at the University of Alicante have developed high-precision software for diagnosing eye sensitivity. This is a new technology that allows to quantify the degree of opacity in the posterior capsule of the eye caused by the growth of cells in the intraocular lens. [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
Cataract surgery for people with dementia slows cognition decline, improves quality of life

Cataract surgery for people with dementia slows cognition decline, improves quality of life

Cataract surgery for people with Alzheimer's disease and other dementias not only improves vision but can slow decline in cognition and improve quality of life for both people with the disease and their caregivers, according to clinical trial results reported today at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen. [More]
Quantel Medical receives FDA clearance for Optimis Fusion integrated laser platform

Quantel Medical receives FDA clearance for Optimis Fusion integrated laser platform

Quantel Medical today announced FDA 510(k) clearance for its Optimis Fusion integrated laser platform. The Optimis Fusion system combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to offer ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform. [More]

Vitreous anatomic features characterised

Researchers have found a direct anteroposterior connection between the retrolental and premacular and preoptic spaces that exits in young adults before the occurrence of vitreous degeneration. [More]
Researchers find unique cell type that can protect against uveitis

Researchers find unique cell type that can protect against uveitis

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss. [More]
BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma. [More]
Study links nearsightedness to higher education and years spent in school

Study links nearsightedness to higher education and years spent in school

German researchers have found strong evidence that attaining a higher level of education and spending more years in school are two factors associated with a greater prevalence and severity of nearsightedness, or myopia. [More]

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its Phase 2b trial for once-daily, quadruple-action RoclatanTM, a combination of Aerie's triple-action RhopressaTM with latanoprost, a prostaglandin analogue (PGA). [More]
University Hospitals introduces surgical procedure for management of glaucoma in NE Ohio

University Hospitals introduces surgical procedure for management of glaucoma in NE Ohio

With the arrival of a leading expert in glaucoma, Douglas Rhee, MD, as its chairman of the Department of Ophthalmology and Visual Sciences, University Hospitals Case Medical Center is introducing a surgical procedure for the management of glaucoma that is new to Northeast Ohio. [More]